Zoetis Inc. (NYSE:ZTS) Shares Sold by Addison Advisors LLC

Addison Advisors LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 8.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,195 shares of the company’s stock after selling 104 shares during the period. Addison Advisors LLC’s holdings in Zoetis were worth $195,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC raised its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after buying an additional 4,829,815 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Zoetis by 296.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock worth $144,917,000 after acquiring an additional 665,331 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares in the last quarter. Holocene Advisors LP acquired a new stake in shares of Zoetis during the third quarter valued at approximately $110,809,000. Finally, Fisher Funds Management LTD purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $66,123,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $215.40.

Zoetis Trading Up 2.0 %

NYSE:ZTS opened at $168.60 on Wednesday. The company has a market capitalization of $75.50 billion, a P/E ratio of 30.82, a P/E/G ratio of 2.78 and a beta of 0.90. The stock’s 50 day moving average price is $166.26 and its 200 day moving average price is $177.66. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.19%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.